Key Takeaways
- Profit crosses full-year mark in nine months: PAT of Rs. 98 crores for 9M FY25 already exceeds the Rs. 96 crores earned in all of FY24, driven by a European export surge and operating efficiencies.
- China price cycle is turning, but the benefit is not yet booked: Chinese raw material prices have started rising after a long decline that forced 40% extra production just to hold revenue flat. Management expects selling price upside in "one quarter transition," but the market has not responded yet.
- Medical devices are taking share and adding monetization: The segment grew 15% YoY in Q3, now 29% of nine-month revenue, while the strips-per-meter ratio improved from 150 to 165–167, signalling better recurring pull-through from the 1.35 crore installed meter base.
- Margins compressed on a temporary API squeeze: EBITDA margin dipped to 10.72% for nine months as raw material costs rose ahead of finished product prices and high production volumes kept opex elevated. Management calls the compression API-specific and temporary.
- What to watch next quarter: Whether the China price upside actually flows into selling prices, the pace of medical device export order conversion after MEDICA and Arab Health, and any margin recovery as the raw material-to-finished-product price lag closes.
China Price Cycle & API Margin Dynamics
- The drag that was: Chinese prices fell for two years, forcing the company to produce 40% more goods just to hold turnover flat. That excess production kept operational expenses high relative to revenue, compressing gross margins even as volumes rose.
- The turn: China has now exhausted its excess inventories, raw material prices have started rising, and the price drop appears halted. In nine months, production rose only 10% versus 40% in the prior full year, a sign the volume treadmill is slowing.
- The lag: Finished product selling prices have not yet responded to the raw material uptick, so the margin benefit is still pending. Management expects an upside in "one quarter transition" but notes the market has not moved yet.
- Quantity vs. value gap narrowing: Despite price pressure, 11% more quantity was sold in APIs (307 MT to 341 MT), yielding only 3.6% revenue growth. As prices stabilize, that volume growth should convert more fully into revenue.
- Margin volatility is structural in B2B: Management frames API margin swings as routine: one supplier changes a price and the whole costing shifts. The compression is not seen as a permanent reset but as a frequent, fast-reverting fluctuation.
Sushil Suri: "The way I look at it that okay these margin profile is temporary because prices in B2B things come up and down very fast and frequent. So, because one supplier changes one price and our whole costing goes up and down. That doesn't mean that the margin has gone down or up."
Medical Devices: The Growth Engine
- Scale and share rising: Q3 revenue grew 15% YoY to Rs. 123 crores; nine-month growth was 11% (Rs. 354 crores to Rs. 394 crores). The segment's share of total revenue increased from 26% to 29% for the nine-month period, and management expects that share to keep rising as device growth outpaces API and pharma generics.
- Razor-and-blade model deepening: The installed base of glucometers reached 1.35 crore (up from 1.16 crore last March). Strips sold per meter improved from 150 to 165–167, meaning each meter is generating more recurring revenue. The company sold 33 crore strips in nine months versus 36 crore in all of last year.
- Capacity constraints resolved: Q1 saw demand outstrip capacity. New production lines have since been laid, and a 120,000 sq ft medical device facility is now complete with civil work done. A 10,000 sq ft screen printing plant for LED screens is operational, freeing space for BP monitor expansion in the existing building.
- Indigenization lifting margins: BP monitors are now 100% indigenized: injection molding in-house, PCBs made in-house (only bare PCBs imported), SMT lines and chip mounting done internally. Margins are improving as a result of these cost reductions.
- Export push beginning: The team exhibited at MEDICA Germany and Arab Health Dubai, receiving queries for ortho products, contract manufacturing, and technology. Product launches occurred in Qatar and Oman; a branded medical device store is opening in Bangkok. Management expects devices export to start contributing in 12–18 months.
- Penetration runway is long: Management estimates only 30–40% penetration in diabetes and BP monitoring, with roughly 10 crore diabetics in India per WHO estimates. The company sees at least another 10 years of open opportunity, amplified by mobile connectivity and telemedicine.
Sushil Suri: "I am seeing at least for another 10 years, we are seeing an open platform, open canvas and the story would be written year-after-year and coupled with the technology, thanks to mobile then connected devices and telemedicine. So, this is a place where we will be there for life."
Export Markets: Europe Surges, US Stalls
- Europe recovery after years of drought: The European market had been slow for 3–4 years post-COVID but has started coming up. Nine-month revenue jumped 55% (Rs. 97 crores to Rs. 151 crores), adding materially to profitability.
- Nine-month export milestone: Total exports crossed Rs. 500 crores in nine months, the highest ever in Morepen's history. The company expects to easily cross Rs. 650–700 crores in exports for the full year.
- US market down on political uncertainty: US revenue declined 14% in nine months. Management attributes this to the election year and instability, noting they are not expecting many orders and may end up with flat sales in the US next quarter.
- Domestic market deliberately deprioritized: India revenue was kept low (~5% down) as a strategic choice. The domestic market is described as very competitive and demanding; the company prefers to focus on exports. For Montelukast specifically, the company is purposely supplying less domestically because it is not very profitable.
- China-plus-one tailwind: The CDMO opportunity is being driven by innovators who lack large-scale manufacturing facilities, with Loratadine (produced for 30 years, largest producer) as a key contract manufacturing product. The China-plus-one model is pushing demand toward high-end Indian manufacturing.
Sushil Suri: "Rs. 500 crore export in nine months itself is a landmark. So, we never had a Rs. 500 crore export in nine months. So, this itself is the highest ever in the Morepen history."
Capacity Build-Out & Product Pipeline
- API capacity doubling underway: The P8 plant was inaugurated during the quarter with 60 KL capacity (6 big reactors, 2 small reactors). P9 block construction has started and will act faster. Management expects all 600 KL to be ready for execution within 6–9 months.
- New molecule mix improving: New molecules' share of API revenue rose from 10% to 12.4%. Going forward, their share will keep increasing while legacy products like Loratadine, Desloratadine, and Montelukast may see only nominal growth.
- Patent expiry pipeline: Empagliflozin patent expires in March; Sitagliptin patent expiry is happening worldwide in 2026 and 2027. Around 40 products with patent expiries are lined up over the next 3–5 years.
- Formulation and OTC launches: LightLife weight management range launched in December (pre-meal drink sachet and meal-on-the-go protein shake) using patented Slim Biome and Intelicaps technologies. Two new Rx products launched: Ticaspan (ticagrelor, antiplatelet) and UdoFix (UDCA, liver health). Farah Khan retained as brand ambassador for OTC.
- Digital ecosystem building: The Dr. Morepen-Sync app launched to sync BP, glucose, and weight data via keyboard, meter scan, or voice. It records readings, creates graphs, gives alerts, and provides dietary guidance. This is a precursor to a Bluetooth-enabled model that will auto-capture data.
The Margin Roadmap: From API to Formulations
- Current margin profile: EBITDA margin stands at 10.72% for nine months. The near-term guidance is 11–12%, with management noting that while formulation and OTC carry higher margins, their revenue contribution is still small so the blended number remains API-driven for now.
- The 10x formulation math: Converting API to finished dosage multiplies revenue roughly 10x: API cost is only about 10% of the formulation selling price. If API sells for $100, the formulation sells for roughly $1,000, though it requires additional effort and regulatory approvals.
- Long-term margin target: Management aims for 15% EBITDA margin over the long term. The drivers: shifting mix toward finished dosages (which carry 20–25% EBITDA margin), medical devices export, and reducing exposure to low-margin traditional APIs. Domestic finished dosage growth will be slower; the export facility is operational with two new product launches coming from it.
- Formulation and OTC growth ambition: At least 25% growth expected for formulation and OTC taken together. The company is seeing lots of demand for finished dosages from India.
- Q4 margin visibility is low: Management declined to guide on Q4 margins, saying it is too early to comment. Prices are forming up but demand needs time to come. March quarter is typically quiet for trade businesses (finished dosage and medical devices) due to income tax and GST pressures, while API is usually good as international customers place orders after year-end closing.
Sushil Suri: "If I convert that API into formulation, so I got 10x revenue. Of course, I have to do a little more effort to convert it and to get approval. So, if I jumble up, finished dosage, the API cost is only 10%. Instead of selling API for $100, if I make a formulation, it will sell for $1,000."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Full-year EPS | Rs. 2.5 (TTM currently 2.39) | FY25 |
| Pharma revenue | Rs. 1,150–1,200 crores | FY25 |
| Medical devices revenue | Rs. 470–475 crores | FY25 |
| Total exports | Crossing Rs. 650–700 crores | FY25 |
| API capacity | All 600 KL ready for execution | Within 6–9 months |
| Revenue growth | 10–15% bare minimum; higher if China prices stabilize | Ongoing |
| Long-term CAGR | 20% | Long term |
| Formulation + OTC growth | At least 25% | Ongoing |
| Near-term EBITDA margin | 11–12% | While formulation share is still small (1–2 years) |
| Long-term EBITDA margin | 15%, driven by finished dosage mix shift and devices export | Long term |
| Medical devices export contribution | Start contributing | 12–18 months |
| Finished dosage export | Start | 2–3 years |
| CDMO scientific lab | May come up | About one year ("still not on the cards") |
Key Metrics
| Metric | Q3 FY25 |
|---|---|
| Revenue (quarterly) | ₹458 cr, up 2% YoY from ₹449 cr |
| Revenue (nine months) | ₹1,359 cr, up 6.5% YoY from ₹1,277 cr |
| EBITDA (quarterly) | ₹41 cr, down 24% YoY; margin 9.05% vs 12% last year |
| EBITDA (nine months) | up 21% YoY; margin 10.71% vs ~10% last year |
| Profit after tax (quarterly) | ₹27 cr, vs ₹34 cr in Q3 FY24 |
| Profit after tax (nine months) | ₹97.71 cr, up 44% YoY; exceeds full FY24 PAT of ₹96 cr |
| EPS (quarterly) | ₹0.49 |
| EPS (trailing 12 months) | ₹2.39, targeting ₹2.5 for full year |
| Pharma segment revenue (quarterly) | ₹335 cr; nine months ₹966 cr |
| Medical devices revenue (quarterly) | ₹123 cr, up 15% YoY from ₹107 cr; nine months ₹394 cr, up 11% YoY |
| Medical devices share of total revenue | 29% for nine months, up from 26% last year |
| Exports (nine months) | ₹500 cr, up 10% YoY; highest ever for nine months |
| API business growth (nine months) | 3.6% YoY; quantity sold up 11% to 341 MT |
| Rx and OTC business growth (nine months) | 8% YoY |
| Glucometer installed base | 1.35 cr meters, up from 1.16 cr in March 2024 |
| Glucometer strips sold (nine months) | 33 cr strips; last full year 36 cr |
| BP monitor installed base | 0.67 cr meters |
| BP monitors sold (nine months) | 9.5 lakh units, up from 8.48 lakh last year |
| US market revenue (nine months) | ₹102 cr, down 14% YoY from ₹119 cr |
| Europe market revenue (nine months) | ₹151 cr, up 55% YoY from ₹97 cr |
| API capacity | 510 KL operational; total planned 600 KL per QIP |
| FY25 estimated revenue | ~₹1,900 cr, ~7% growth (per an analyst's math; management noted 10-11% growth but not official guidance) |